pabociclib + talazoparib + atezolizumab

This is a combination therapy consisting of three agents: - **Pabociclib (palbociclib)** is an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression from G1 to S phase. - **Talazoparib** is an oral small molecule poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in tumor cells with homologous recombination deficiency by preventing DNA repair. - **Atezolizumab** is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and B7.1 receptors to enhance anti-tumor immune response. This combination is being investigated for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer—particularly in premenopausal women or those harboring homologous recombination deficiency scars. The rationale for this regimen lies in combining targeted cell cycle inhibition (pabociclib), impaired DNA repair (talazoparib), and immune checkpoint blockade (atezolizumab) to achieve synergistic anti-cancer effects[2][3][4][5].

Brand names

Ibrance

Other names

palbociclib + talazoparib + atezolizumab